Home/Filings/4/0000950170-25-085047
4//SEC Filing

Detheux Michel 4

Accession 0000950170-25-085047

CIK 0001808865other

Filed

Jun 10, 8:00 PM ET

Accepted

Jun 11, 9:01 PM ET

Size

33.0 KB

Accession

0000950170-25-085047

Insider Transaction Report

Form 4
Period: 2025-06-09
Detheux Michel
Chief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-06-09$4.30/sh+8,400$36,120144,303 total
  • Sale

    Common Stock

    2025-06-09$10.03/sh8,400$84,252135,903 total
  • Exercise/Conversion

    Common Stock

    2025-06-09$4.30/sh+43,882$188,69343,882 total(indirect: By MG3A)
  • Sale

    Common Stock

    2025-06-09$10.03/sh43,882$440,1360 total(indirect: By MG3A)
  • Exercise/Conversion

    Common Stock

    2025-06-10$4.30/sh+18,000$77,400153,903 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-06-098,40026,400 total
    Exercise: $4.30From: 2022-07-01Exp: 2025-06-11Common Stock (8,400 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-06-108,40018,000 total
    Exercise: $4.30From: 2022-07-01Exp: 2025-06-11Common Stock (8,400 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-06-1094,0273 total(indirect: By MG3A)
    Exercise: $4.30From: 2022-07-01Exp: 2025-06-11Common Stock (94,027 underlying)
  • Exercise/Conversion

    Common Stock

    2025-06-10$4.30/sh+8,400$36,120144,303 total
  • Sale

    Common Stock

    2025-06-10$10.02/sh8,400$84,168135,903 total
  • Exercise/Conversion

    Common Stock

    2025-06-10$4.30/sh+43,883$188,69743,883 total(indirect: By MG3A)
  • Sale

    Common Stock

    2025-06-10$10.02/sh43,883$439,7080 total(indirect: By MG3A)
  • Exercise/Conversion

    Common Stock

    2025-06-10$4.30/sh+94,027$404,31694,027 total(indirect: By MG3A)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-06-0943,882137,913 total(indirect: By MG3A)
    Exercise: $4.30From: 2022-07-01Exp: 2025-06-11Common Stock (43,882 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-06-1018,0000 total
    Exercise: $4.30From: 2022-07-01Exp: 2025-06-11Common Stock (18,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-06-1043,88394,030 total(indirect: By MG3A)
    Exercise: $4.30From: 2022-07-01Exp: 2025-06-11Common Stock (43,883 underlying)
Footnotes (6)
  • [F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.17, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.98 to $10.17, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.99 to $10.06, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F6]This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.

Documents

1 file

Issuer

iTeos Therapeutics, Inc.

CIK 0001808865

Entity typeother

Related Parties

1
  • filerCIK 0001816196

Filing Metadata

Form type
4
Filed
Jun 10, 8:00 PM ET
Accepted
Jun 11, 9:01 PM ET
Size
33.0 KB